6533b7d8fe1ef96bd126b795

RESEARCH PRODUCT

Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level

Jessica MartínezAna CastroVíctor Rodríguez-garcíaJuan J. TarínAntonio CanoRaúl GómezOctavio Burgués

subject

0301 basic medicineEndometriumRANKlcsh:Chemistry0302 clinical medicineGene expressionProtein IsoformsendometriumReceptorlcsh:QH301-705.5SpectroscopyReceptor Activator of Nuclear Factor-kappa BbiologyGeneral MedicineMiddle AgedComputer Science ApplicationsGene Expression Regulation Neoplasticmedicine.anatomical_structureRANKL030220 oncology & carcinogenesisendometrial cancerimmunohistochemistryImmunohistochemistryFemaleAdultGene isoformAdenocarcinomaArticleCatalysisInorganic Chemistry03 medical and health sciencesmedicineHumansRNA MessengerPhysical and Theoretical ChemistryMolecular BiologyNeoplasm StagingActivator (genetics)Endometrial cancerOrganic Chemistrymedicine.diseaseEndometrial NeoplasmsAlternative Splicing030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Tissue Array Analysisgene expressionCancer researchbiology.proteinprognosisNeoplasm Grading

description

The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p &lt

yearjournalcountryeditionlanguage
2018-06-22International Journal of Molecular Sciences
https://doi.org/10.3390/ijms19071848